Updated:
Mayo Clinic Ventures
Mayo Clinic Ventures operates as the corporate venture arm of the Mayo Clinic, one of the world's largest integrated academic medical centers.
Mayo Clinic Ventures
Mayo Clinic Ventures operates as the corporate venture arm of the Mayo Clinic, one of the world's largest integrated academic medical centers. Unlike a financial venture fund, its mandate stems from the institution's clinical and research priorities—deploying Mayo's balance-sheet capital into companies whose technologies can plausibly enter Mayo's own care-delivery system. The unit traces its origin to the mid-1980s, formalizing a practice of commercializing internally developed intellectual property and, over time, extending to external direct investments. It remains embedded within the Rochester, Minnesota-based Mayo Clinic enterprise. The portfolio spans early-stage through growth-equity deals across medical devices, diagnostics, digital health platforms, and healthcare IT. Sectors of confirmed activity include precision-medicine diagnostics, AI-driven clinical decision-support software, and novel therapeutic-delivery devices. Mayo Clinic Ventures has historically participated in syndicates alongside traditional life-science VCs such as OrbiMed and New Enterprise Associates, while also leading rounds where clinical validation at Mayo provides a signal that pure financial investors cannot replicate. Portfolio companies have included Doctella, a patient-engagement platform; Ambient Clinical Analytics, a Mayo-born clinical decision-support spinout; and BioSig Technologies, a cardiac arrhythmia mapping company. The geographic footprint concentrates on US-based companies, with select investments in European and Israeli health-tech firms that demonstrate regulatory pathways into US markets. The unit's investment committee draws on practicing Mayo physicians and research leaders, an architecture that bakes clinical-use-case evaluation directly into the diligence process. In June 2023, Mayo Clinic announced a partnership with Techcyte, a digital pathology company, where the venture unit's investment accompanied a broader clinical collaboration—illustrating the unit's model of coupling equity with enterprise adoption. This dual-track approach means the venture unit reports through Mayo's corporate development function rather than a standalone fund structure, consuming little outside LP capital and facing minimal redemption risk. What structurally differentiates Mayo Clinic Ventures is its role as a balance-sheet investor inside a non-profit health system. The unit does not raise funds, deploy against a vintage-year deadline, or mark positions to satisfy quarterly LP reporting. That permanent-capital posture lets it hold companies through regulatory cycles that would exhaust a standard 10-year fund—a genuine advantage in FDA-dependent sectors. Governance runs through Mayo's Board of Trustees, meaning exits are evaluated against patient-mission impact as much as multiple on invested capital.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Rochester
Corporate office
Rochester, MN, United States
Sector focus
Frequently asked questions
What is the core investment thesis for Mayo Clinic Ventures?
Mayo Clinic Ventures invests in companies whose technologies directly align with Mayo's clinical and research mission, with the expectation that Mayo's clinicians can serve as development partners or early adopters. The thesis is anchored in deploying the institution's balance sheet, not third-party LP capital. Every investment requires a clinical champion within Mayo who validates the technology's potential impact on patient care.
How is Mayo Clinic Ventures governed, and who makes the investment decisions?
The unit operates under Mayo Clinic's corporate umbrella and reports through the institution's corporate development function rather than through an external GP structure. Investment committees draw on practicing Mayo physicians and researchers alongside venture professionals, giving clinical-use-case evaluation a direct seat at the table. Ultimate governance rests with Mayo's Board of Trustees, which evaluates both financial returns and mission alignment.
Is Mayo Clinic Ventures a fund structure that takes outside LP capital?
No. Mayo Clinic Ventures deploys capital directly from Mayo Clinic's own balance sheet and does not raise third-party LP commitments. This makes it a corporate venture capital entity rather than a traditional fund—the unit faces no fundraising cycles and is not bound by the typical 10-year fund-life constraints that shape conventional VC behavior.
Which sectors does Mayo Clinic Ventures focus on, and which does it avoid?
The portfolio concentrates on medical devices, diagnostics, digital health, healthcare IT, and AI-driven clinical software. The unit avoids areas disconnected from its clinical enterprise—consumer wellness without a clinical pathway, pure pharmaceutical plays without a companion diagnostic component, or therapeutic assets where Mayo lacks internal clinical research depth. Investments outside US healthcare are rare unless a clear FDA regulatory pathway exists.
Does Mayo Clinic Ventures invest alongside external venture capital firms?
Yes. The unit frequently co-invests in syndicates with life-science VCs including OrbiMed and New Enterprise Associates. Mayo's stance is that its clinical validation signal can complement pure financial VC diligence. The unit also acts as a lead investor on rounds where Mayo's clinical partnership offers the startup a deployment edge that financial VCs alone cannot provide.
How does Mayo Clinic Ventures handle exits, given its parent institution is a non-profit?
Exits are evaluated against a dual metric: financial return—which flows back to Mayo's clinical and research operations—and mission impact, meaning whether the technology reached patients through Mayo's own system or the broader market. The unit's permanent-capital posture allows it to hold positions through lengthy FDA regulatory processes without forced secondary sales or fire-sale liquidity events.
How does a startup get on Mayo Clinic Ventures' radar for an investment?
Deal flow originates primarily from Mayo's own clinical and research staff—a network of roughly 7,000 physicians and scientists who encounter emerging technologies in the course of their work. External founders typically gain access by presenting to a Mayo clinician willing to champion the technology internally. The unit does not accept unsolicited pitch decks without a clinical-advocate introduction, a filtering mechanism that distinguishes it from volume-driven venture platforms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: